WHATNEXT.com

WHATNEXT is grateful to our partner Elephants & Tea for providing the following article by Laura DeKraker Lang-Ree, a cancer caregiver to her daughter Cecilia who survived childhood leukemia. Elephants & Tea‘s mission is to help adolescent and young adult (AYA) patients, survivors, and caregivers know they are not alone in their experience with cancer. The Elephant in the room is cancer. Tea is the relief conversation provides.

When Steven was first diagnosed with Waldenstrom’s Macroglobulinemia, a rare blood cancer, he was worried and confused. Years later, he now advocates for lower drug prices and equal access to care. Read more of Steven’s story here at PatientWorthy.com: https://patientworthy.com/2025/06/13/waldenstroms-macroglobulinemia-advocacy-stevens-story/ Cancer doesn’t discriminate. WHATNEXT and its partners are interested in amplifying the voices of those from all identities and backgrounds.

We’re honored to bring you this video, shared with us by Danny Gereg, that details some of his journey living with bladder cancer. Danny has stayed resilient and positive, finding strength and community in the face of his diagnosis. Through lifestyle changes and interpersonal connection, he’s been able to turn a lifechanging event into a new future, and has devoted himself full-time to advocacy and awareness.

On April 10, 2022, I was headed out for a round of golf in the North Georgia mountains when I suddenly noticed blood in my urine. Alarmed, I went straight to the ER at Northside Hospital in Atlanta. After scans and evaluations, they discovered a kidney stone and referred me to a urologist for follow-up. That led me to Dr. Wesley Ludwig, who confirmed the stone, but during further testing, including a cystoscopy, he discovered I also had bladder cancer. That was a shock.

Daiichi Sankyo and MSD have announced positive results from a Phase III clinical trial evaluating their antibody-drug conjugate trastuzumab deruxtecan in patients with previously treated HER2-positive unresectable or metastatic esophageal cancer, according to Clinical Trials Arena. The findings mark a significant advancement in the treatment options for this aggressive cancer type, which is often diagnosed at an advanced stage and carries a poor prognosis.

According to a report from AllAfrica, Tanzania has launched a new initiative to improve early cancer detection and treatment across the country, aiming to combat rising cancer rates and reduce mortality. The program, spearheaded by the Tanzanian government in partnership with healthcare organizations, focuses on expanding access to screening services, increasing public awareness, and strengthening the country’s treatment infrastructure.

AstraZeneca has marked a significant milestone by presenting plenary data for the seventh consecutive year at the American Society of Clinical Oncology (ASCO) Annual Meeting, underscoring its commitment to transforming cancer care. According to a press release issued by the company on May 21, 2025, these latest data further AstraZeneca’s ambition to redefine standards of treatment in breast and gastric cancers.

ME Therapeutics has announced it is receiving new support to accelerate the development of its mRNA-based therapeutic candidates, targeting cancer and inflammatory diseases. According to a press release published by the Financial Post on May 21, 2025, this support will help the company move forward with research, preclinical studies, and preparations for future clinical trials.

Silexion Therapeutics has announced the successful completion of important preclinical studies investigating the potential of its novel drug candidate, SIL204, for the treatment of colorectal and lung cancer. According to a press release published by GlobeNewswire, the results mark a significant milestone for the company as it prepares for the next stages of drug development. The preclinical studies evaluated the effectiveness and safety of SIL204 in laboratory and animal models.

Current treatments have not been effective against cancers of the female reproductive system. The result is that ovarian cancer remains a primary cause of death from cancers that have metastasized (spread). A New Direction Recently a study identified an essential factor indicating a promising new path for targeted strategies. Targeted therapy, a treatment using drugs to attack cancer cells, differentiates them from healthy cells.